Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Dermatology | Infections | Nursing | Pharmacy | Journal

Back to Journal Articles

Tedizolid Phosphate Viable for Bacterial Skin Infections

Last Updated: February 13, 2013.

 

Tedizolid phosphate noninferior to linezolid in phase 3 trial, with good early clinical response

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Six days of tedizolid phosphate treatment is noninferior to a 10-day course of linezolid for treating acute bacterial skin and skin structure infections, according to a study published in the Feb. 13 issue of the Journal of the American Medical Association.

WEDNESDAY, Feb. 13 (HealthDay News) -- Six days of tedizolid phosphate treatment is noninferior to a 10-day course of linezolid for treating acute bacterial skin and skin structure infections (ABSSSIs), according to a study published in the Feb. 13 issue of the Journal of the American Medical Association.

Philippe Prokocimer, M.D., from Trius Therapeutics Inc. in San Diego, and colleagues conducted a phase 3 noninferiority trial at 81 study centers involving 667 adults aged 18 years or older with ABSSSIs. Participants were randomly allocated to receive treatment with a once-daily dose of 200 mg oral tedizolid phosphate for six days (332 patients) or 600 mg of oral linezolid every 12 hours for 10 days (335 patients).

The researchers found that the early clinical treatment response rates were 79.5 percent in the tedizolid phosphate group and 79.4 percent in the linezolid group. At the end of treatment (day 11), the sustained clinical treatment response rates were 69.3 and 71.9 percent, respectively. At a post-therapy evaluation visit (one to two weeks after the end-of-treatment visit), the investigator-assessed clinical treatment success rates were 85.5 and 86.0 percent, respectively, and were similar for the 178 patients with methicillin-resistant Staphylococcus aureus in the primary lesion.

"A short course of tedizolid phosphate was statistically noninferior to a 10-day course of linezolid for both early and sustained clinical responses in patients with ABSSSIs," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including the manufacturer of tedizolid phosphate Trius Therapeutics, which funded and conducted the trial.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Health News Copyright © 2013 HealthDay. All rights reserved.


Previous: ASCO: Many Still Diagnosed With Higher-Risk Prostate Cancer Next: IBCERCC: Prioritize Prevention to Reduce Breast Cancer

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.